Outlook Therapeutics Inc Stock Alpha and Beta Analysis
| OTLK Stock | USD 2.01 0.31 18.24% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as OUTLOOK THERAPEUTICS INC. It also helps investors analyze the systematic and unsystematic risks associated with investing in OUTLOOK THERAPEUTICS over a specified time horizon. Remember, high OUTLOOK THERAPEUTICS's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to OUTLOOK THERAPEUTICS's market risk premium analysis include:
Beta (0.62) | Alpha (0.77) | Risk 9.93 | Sharpe Ratio (0.08) | Expected Return (0.75) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
OUTLOOK |
OUTLOOK THERAPEUTICS Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. OUTLOOK THERAPEUTICS market risk premium is the additional return an investor will receive from holding OUTLOOK THERAPEUTICS long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in OUTLOOK THERAPEUTICS. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate OUTLOOK THERAPEUTICS's performance over market.| α | -0.77 | β | -0.62 |
OUTLOOK THERAPEUTICS expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of OUTLOOK THERAPEUTICS's Buy-and-hold return. Our buy-and-hold chart shows how OUTLOOK THERAPEUTICS performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.OUTLOOK THERAPEUTICS Market Price Analysis
Market price analysis indicators help investors to evaluate how OUTLOOK THERAPEUTICS stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading OUTLOOK THERAPEUTICS shares will generate the highest return on investment. By understating and applying OUTLOOK THERAPEUTICS stock market price indicators, traders can identify OUTLOOK THERAPEUTICS position entry and exit signals to maximize returns.
OUTLOOK THERAPEUTICS Return and Market Media
The median price of OUTLOOK THERAPEUTICS for the period between Mon, Sep 30, 2024 and Sun, Dec 29, 2024 is 5.19 with a coefficient of variation of 43.88. The daily time series for the period is distributed with a sample standard deviation of 1.87, arithmetic mean of 4.27, and mean deviation of 1.69. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Thurman Randy H of 89549 shares of OUTLOOK THERAPEUTICS at 5.22 subject to Rule 16b-3 | 10/09/2024 |
2 | Acquisition by Auffarth Gerd of 56636 shares of OUTLOOK THERAPEUTICS at 5.22 subject to Rule 16b-3 | 10/11/2024 |
3 | Great Point Partners LLC Bolsters Position in Outlook Therapeutics Inc | 11/15/2024 |
4 | Owning 30 percent shares,institutional owners seem interested in Outlook Therapeutics, Inc. , | 11/26/2024 |
5 | Outlook Therapeutics Announces Preliminary Topline Results of N | 11/27/2024 |
6 | Investors Purchase Large Volume of Call Options on Outlook Therapeutics | 11/29/2024 |
7 | UK productivity crisis worse than feared amid migration surge | 12/03/2024 |
8 | Muhammad most popular boys baby name in England and Wales for first time | 12/06/2024 |
9 | UK economy shrinks again in October in blow to Starmers budget - live updates | 12/13/2024 |
10 | Thinking to buy more of OUTLOOK THERAPEUTICS | 12/19/2024 |
11 | Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -4.06, Missing Revenue Estimate of 0. ... | 12/27/2024 |
About OUTLOOK THERAPEUTICS Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including OUTLOOK or other stocks. Alpha measures the amount that position in OUTLOOK THERAPEUTICS INC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2017 | 2023 | 2024 (projected) | Dividend Yield | 13.2K | 11.9K | 12.5K | Price To Sales Ratio | 46.19 | 2.99 | 2.84 |
OUTLOOK THERAPEUTICS Upcoming Company Events
As portrayed in its financial statements, the presentation of OUTLOOK THERAPEUTICS's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, OUTLOOK THERAPEUTICS's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of OUTLOOK THERAPEUTICS's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of OUTLOOK THERAPEUTICS. Please utilize our Beneish M Score to check the likelihood of OUTLOOK THERAPEUTICS's management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with OUTLOOK THERAPEUTICS
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out OUTLOOK THERAPEUTICS Backtesting, OUTLOOK THERAPEUTICS Valuation, OUTLOOK THERAPEUTICS Correlation, OUTLOOK THERAPEUTICS Hype Analysis, OUTLOOK THERAPEUTICS Volatility, OUTLOOK THERAPEUTICS History and analyze OUTLOOK THERAPEUTICS Performance. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
OUTLOOK THERAPEUTICS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.